Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Zenas Biopharma Inc's Business Segments

Zenas Biopharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q1 FY2025

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Single Reportable Segment

100% of revenue

Total Revenue

$ 10

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ZBIO/segments                    

                        https://api.csimarket.com/api/v1/companies/ZBIO/geographic                    

                        https://api.csimarket.com/api/v1/companies/ZBIO/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - Q1 FY2025

Single Reportable Segment100%

Revenue by Reportable Segment - Q1 FY2025

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Single Reportable Segment	Q1 FY2025	$ 10	100%	-

Description of Zenas Biopharma Inc

The company is a clinical-stage global biopharmaceutical firm focused on developing and commercializing immunology-based therapies for autoimmune diseases. Its strategy includes acquiring product candidates and utilizing internal and external expertise to develop treatments for immune and inflammatory diseases. The lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb on B cells to inhibit their activity without depletion. Obexelimab has demonstrated clinical activity and safety in eight trials, including Phase 3 and Phase 2 studies for immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS), and systemic lupus erythematosus (SLE). Positive Phase 3 results in IgG4-RD support planned regulatory submissions in 2026. The company is also developing orelabrutinib, a selective, CNS-penetrant Bruton’s Tyrosine Kinase inhibitor for progressive multiple sclerosis, currently in Phase 3 trials. Early-stage candidates include ZB021, an oral IL-17AA/AF inhibitor, and ZB022, a brain-penetrant TYK2 inhibitor, both expected to enter clinical trials in 2026. Additional programs include ZB002 (anti-TNFα antibody), ZB004 (CTLA-4-Ig fusion), and ZB001 (IGF-1R antibody), which are licensed regionally. To date, the company has no approved products or revenue. Bristol Myers Squibb & Co. holds exclusive rights to obexelimab in select Asia-Pacific countries.

The company operates a single reportable segment dedicated to the research and development of precision immunology-based therapies. The Chief Executive Officer serves as the chief operating decision-maker, overseeing consolidated operations for decision-making, financial performance assessment, and resource allocation.